Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes
- PMID: 22302016
- PMCID: PMC3297690
- DOI: 10.1158/1055-9965.EPI-11-0741
Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes
Abstract
Background: Genome-wide association studies (GWAS) for epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy, have identified novel susceptibility loci. GWAS for survival after EOC have had more limited success. The association of each single-nucleotide polymorphism (SNP) individually may not be well suited to detect small effects of multiple SNPs, such as those operating within the same biologic pathway. Gene set analysis (GSA) overcomes this limitation by assessing overall evidence for association of a phenotype with all measured variation in a set of genes.
Methods: To determine gene sets associated with EOC overall survival, we conducted GSA using data from two large GWAS (N cases = 2,813, N deaths = 1,116), with a novel Principal Component-Gamma GSA method. Analysis was completed for all cases and then separately for high-grade serous histologic subtype.
Results: Analysis of the high-grade serous subjects resulted in 43 gene sets with P < 0.005 (1.7%); of these, 21 gene sets had P < 0.10 in both GWAS, including intracellular signaling pathway (P = 7.3 × 10(-5)) and macrolide binding (P = 6.2 × 10(-4)) gene sets. The top gene sets in analysis of all cases were meiotic mismatch repair (P = 6.3 × 10(-4)) and macrolide binding (P = 1.0 × 10(-3)). Of 18 gene sets with P < 0.005 (0.7%), eight had P < 0.10 in both GWAS.
Conclusion: This research detected novel gene sets associated with EOC survival.
Impact: Novel gene sets associated with EOC survival might lead to new insights and avenues for development of novel therapies for EOC and pharmacogenomic studies.
©2012 AACR.
Conflict of interest statement
The authors have no conflict of interest to declare.
Figures
Similar articles
-
Common variants at 19p13 are associated with susceptibility to ovarian cancer.Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Epub 2010 Sep 19. Nat Genet. 2010. PMID: 20852633 Free PMC article.
-
Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.Int J Gynecol Cancer. 2015 Sep;25(7):1232-8. doi: 10.1097/IGC.0000000000000489. Int J Gynecol Cancer. 2015. PMID: 26067864
-
Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.Asian Pac J Cancer Prev. 2016;17(4):1881-6. doi: 10.7314/apjcp.2016.17.4.1881. Asian Pac J Cancer Prev. 2016. PMID: 27221870
-
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1574-84. doi: 10.1158/1055-9965.EPI-14-1270. Epub 2015 Jul 24. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 26209509 Free PMC article. Review.
-
Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions.Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):395-404. doi: 10.1158/1055-9965.EPI-17-0315. Epub 2017 Jun 14. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 28615364 Review.
Cited by
-
Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.Hum Mol Genet. 2014 Nov 15;23(22):6034-46. doi: 10.1093/hmg/ddu300. Epub 2014 Jun 13. Hum Mol Genet. 2014. PMID: 24927736 Free PMC article.
-
Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):446-54. doi: 10.1158/1055-9965.EPI-15-0240. Epub 2016 Jan 8. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26747452 Free PMC article.
-
Integrative gene set analysis: application to platinum pharmacogenomics.OMICS. 2014 Jan;18(1):34-41. doi: 10.1089/omi.2013.0099. Epub 2013 Nov 7. OMICS. 2014. PMID: 24199607 Free PMC article.
-
Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer.Eur J Hum Genet. 2014 Jan;22(1):126-31. doi: 10.1038/ejhg.2013.69. Epub 2013 Apr 17. Eur J Hum Genet. 2014. PMID: 23591404 Free PMC article.
-
Inherited variants in regulatory T cell genes and outcome of ovarian cancer.PLoS One. 2013;8(1):e53903. doi: 10.1371/journal.pone.0053903. Epub 2013 Jan 30. PLoS One. 2013. PMID: 23382860 Free PMC article.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
-
- Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120–7. - PubMed
-
- McGuire V, Jesser CA, Whittemore AS. Survival among U. S. women with invasive epithelial ovarian cancer. Gynecol Oncol. 2002;84:399–403. - PubMed
-
- Hoskins PJ, O’Reilly SE, Swenerton KD, Spinelli JJ, Fairey RN, Benedet JL. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol. 1992;10:1561–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21 CA140879/CA/NCI NIH HHS/United States
- CA148112/CA/NCI NIH HHS/United States
- CA140879/CA/NCI NIH HHS/United States
- R01 CA122443/CA/NCI NIH HHS/United States
- CA136393/CA/NCI NIH HHS/United States
- U19 CA148112/CA/NCI NIH HHS/United States
- CA122443/CA/NCI NIH HHS/United States
- P50 CA136393/CA/NCI NIH HHS/United States
- R01 CA114343/CA/NCI NIH HHS/United States
- 10124/CRUK_/Cancer Research UK/United Kingdom
- R01 CA106414/CA/NCI NIH HHS/United States
- GM86689/GM/NIGMS NIH HHS/United States
- C490/A10119/CRUK_/Cancer Research UK/United Kingdom
- A10119/CRUK_/Cancer Research UK/United Kingdom
- CA114343/CA/NCI NIH HHS/United States
- R21 GM086689/GM/NIGMS NIH HHS/United States
- 10119/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Medical